MedTrace Logo

Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies

NCT02702102 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-03-18

Study results available
· View outcomes & findings →

Summary

This study uses a special type of scan called a positron emission tomography (PET) scan to take pictures of the brain. During the PET scan, a special dye called 11C-PBR28 is injected into the body.

11C-PBR28 sticks to parts of the brain where there is inflammation. The purpose of this study is to see if 11C-PBR28 can detect inflammation in patients with Parkinson's disease dementia or dementia with Lewy bodies.

11C-PBR28 is considered a drug by the Food and Drug Administration. 11C-PBR28 is not a treatment for any disease. Rather, 11C-PBR28 can be used to measure inflammation in the brain.

Conditions

  • Diffuse Lewy Body Disease
  • Dementia With Lewy Bodies
  • Parkinson's Disease Dementia

Interventions

DRUG

11C-PBR28

Up to 20 millicuries

Sponsors & Collaborators

Principal Investigators

  • William Kreisl, MD · Columbia University

  • Patrick Lao, PhD · Columbia University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2019-09-04
Completion
2019-09-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02702102 on ClinicalTrials.gov